Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
暂无分享，去创建一个
Lauren L. Ritterhouse | E. Winer | C. Hudis | L. Carey | W. Barry | H. Rugo | A. Wolff | H. Burstein | D. Dillon | B. Overmoyer | P. Marcom | K. Albain | D. Yardley | B. Moy | A. Partridge | B. Schneider | I. Shapira | S. Tolaney | I. Krop | L. Ritterhouse | F. Shen | C. Dang | M. Ellis | Hao Guo | S. Pernas | K. Fuhrman | M. Baltay | P. Marcom | William T. Barry | Michele Baltay | K S Albain | Bryan P. Schneider | E. P. Winer | A. C. Wolff | Lauren Ritterhouse